Seeking Alpha

Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a...

Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a higher number of deaths among patients who were taking the drug than among those taking a placebo. The study was testing the drug on previously untreated, elderly patients with B-cell chronic lymphocytic leukemia. All other Revlimid trials for chronic lymphocytic leukemia are proceeding. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs